Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 20/20 | 0.75 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.74 |
| ▸ | MYLK4 | Q86YV6 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18827638 | 1.00 | ROCK2 (0.75) | ROCK2ROCK1MYLK4 | |
| SCHEMBL18827640 | 1.00 | ROCK2 (0.75) | ROCK2ROCK1MYLK4 | |
| SCHEMBL19932321 | 0.92 | ROCK2 (0.70) | ROCK2ROCK1MYLK4 | |
| SCHEMBL19932282 | 0.90 | ROCK2 (0.76) | ROCK2ROCK1MYLK4 | |
| SCHEMBL29192343 | 0.88 | ROCK2 (0.84) | ROCK2ROCK1MYLK4 | |
| SCHEMBL21795453 | 0.88 | ROCK2 (0.80) | ROCK2ROCK1MYLK4 | |
| SCHEMBL21790244 | 0.88 | ROCK2 (0.80) | ROCK2ROCK1MYLK4 | |
| SCHEMBL13021521 | 0.88 | ROCK2 (0.77) | ROCK2ROCK1MYLK4 | |
| SCHEMBL25778046 | 0.88 | ROCK2 (0.77) | ROCK2ROCK1MYLK4 | |
| SCHEMBL25777892 | 0.88 | ROCK2 (0.77) | ROCK2ROCK1MYLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023136942-A1 | SYNTHETIC INTERMEDIATES AND IMPROVED PROCESSES FOR PREPARING ROCK INHIBITORS | AERIE PHARMACEUTICALS, INC. (US) | 2023-07-20 | — | — | WO | disclosed |
| EP-3376870-B1 | PROCESS FOR THE PREPARATION OF KINASE INHIBITORS AND INTERMEDIATES THEREOF | AERIE PHARMACEUTICALS INC (US) | 2021-08-11 | — | — | EP | disclosed |
| US-10550087-B2 | Process for the preparation of kinase inhibitors and intermediates thereof | AERIE PHARMACEUTICALS, INC. (US) | 2020-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10550087-B2 | Process for the preparation of kinase inhibitors and intermediates thereof | MAP3K1, MAP3K6, MAP3K7 | ROCK2 202/4885ROCK1 159/4885MYLK4 341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.